PL2007752T3 - Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4 - Google Patents

Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4

Info

Publication number
PL2007752T3
PL2007752T3 PL07754700T PL07754700T PL2007752T3 PL 2007752 T3 PL2007752 T3 PL 2007752T3 PL 07754700 T PL07754700 T PL 07754700T PL 07754700 T PL07754700 T PL 07754700T PL 2007752 T3 PL2007752 T3 PL 2007752T3
Authority
PL
Poland
Prior art keywords
benzoimidazol
pyrazines
pyrimidines
histamine
modulators
Prior art date
Application number
PL07754700T
Other languages
English (en)
Inventor
James P Edwards
David E Kindrachuk
Jennifer D Venable
Christopher M Mapes
Daniel J Pippel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2007752(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2007752T3 publication Critical patent/PL2007752T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
PL07754700T 2006-03-31 2007-03-30 Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4 PL2007752T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78819006P 2006-03-31 2006-03-31
PCT/US2007/008216 WO2007117399A2 (en) 2006-03-31 2007-03-30 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
EP07754700A EP2007752B1 (en) 2006-03-31 2007-03-30 Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor

Publications (1)

Publication Number Publication Date
PL2007752T3 true PL2007752T3 (pl) 2011-02-28

Family

ID=38581554

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07754700T PL2007752T3 (pl) 2006-03-31 2007-03-30 Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4

Country Status (34)

Country Link
US (6) US7507737B2 (pl)
EP (1) EP2007752B1 (pl)
JP (1) JP5066175B2 (pl)
KR (1) KR101054325B1 (pl)
CN (1) CN101460483B (pl)
AR (1) AR059380A1 (pl)
AT (1) ATE478067T1 (pl)
AU (1) AU2007235576B2 (pl)
BR (1) BRPI0710083A2 (pl)
CA (1) CA2648036C (pl)
CO (1) CO6160328A2 (pl)
CR (1) CR10413A (pl)
CY (1) CY1111169T1 (pl)
DE (1) DE602007008545D1 (pl)
DK (1) DK2007752T3 (pl)
EA (1) EA016264B1 (pl)
EC (1) ECSP088815A (pl)
ES (1) ES2348829T3 (pl)
IL (2) IL194453A0 (pl)
ME (1) ME01143B (pl)
MX (1) MX2008012655A (pl)
NI (1) NI200800260A (pl)
NO (1) NO341523B1 (pl)
NZ (1) NZ571691A (pl)
PE (1) PE20080130A1 (pl)
PL (1) PL2007752T3 (pl)
PT (1) PT2007752E (pl)
RS (1) RS51423B (pl)
SI (1) SI2007752T1 (pl)
TW (1) TWI400234B (pl)
UA (1) UA95949C2 (pl)
UY (1) UY30253A1 (pl)
WO (1) WO2007117399A2 (pl)
ZA (1) ZA200809328B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007008859D1 (de) 2006-03-31 2010-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
PL2007752T3 (pl) 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
MX2010013727A (es) * 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Uso de un antagonista h4 de histamina para el tratamiento de adherencias postoperatorias.
MX2010013726A (es) 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
US20100029942A1 (en) 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
TWI498326B (zh) * 2008-06-30 2015-09-01 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
AU2013204436B2 (en) * 2008-06-30 2014-12-04 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
MY159575A (en) * 2009-04-02 2017-01-13 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
CA2828456C (en) * 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
SMT202000084T1 (it) 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2017076888A1 (en) 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US3931195A (en) 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
US4191828A (en) 1976-04-14 1980-03-04 Richardson-Merrell Inc. Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
US4337341A (en) 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
US4190601A (en) 1978-05-31 1980-02-26 Union Carbide Corporation Production of tertiary amines by reductive alkylation
JPS5942396A (ja) 1982-09-02 1984-03-08 Ishihara Sangyo Kaisha Ltd リン酸アミド誘導体およびそれらを含有する殺虫、殺ダニ、殺線虫剤
JPS6130576A (ja) 1984-07-24 1986-02-12 Ube Ind Ltd ２−アミノ−５−シアノピリミジンの製法
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9410031D0 (en) 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
WO1997036898A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
JP2000507591A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6399612B1 (en) 1997-10-06 2002-06-04 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE242241T1 (de) 1999-03-25 2003-06-15 Synthon Bv Imidazopyridinderivate und verfahren zu ihrer herstellung
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DK1194425T3 (da) 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2379585C (en) 1999-09-30 2006-06-20 James W. Darrow Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
ES2239558T3 (es) 2000-04-24 2007-04-01 Teva Pharmaceutical Industries Ltd. Hemitartrato de zolpidem micronizado.
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2002008207A1 (en) 2000-07-21 2002-01-31 Syngenta Participations Ag Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
MXPA03004458A (es) 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
EP1373204B1 (en) 2001-03-09 2016-10-26 Janssen Pharmaceuticals, Inc. Heterocyclic compounds
EP1370250A2 (en) 2001-03-23 2003-12-17 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
WO2002078701A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
ATE409181T1 (de) 2001-05-08 2008-10-15 Univ Yale Proteomimetische verbindungen und verfahren
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
PL369738A1 (pl) 2001-11-05 2005-05-02 Merck Patent Gmbh Hydrazono-malonitryle
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
ATE425753T1 (de) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
PL375964A1 (pl) 2002-09-06 2005-12-12 Janssen Pharmaceutica, N.V. Zastosowanie pochodnych indolilu do wytwarzania leku do leczenia kataru siennego
EP1543011B1 (en) 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
WO2004022060A2 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040105856A1 (en) 2002-12-02 2004-06-03 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
US7365070B2 (en) 2002-12-04 2008-04-29 Ore Pharmaceuticals Inc. Modulators of melanocortin receptor
MXPA05011710A (es) 2003-05-05 2006-01-23 Hoffmann La Roche Derivados de pirimidina con actividad de crf.
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
KR20060056377A (ko) 2003-08-13 2006-05-24 카이론 코포레이션 Ｇｓｋ-3 억제제 및 그것의 사용
WO2005028447A1 (en) 2003-09-22 2005-03-31 S*Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
RU2006110561A (ru) 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) Соединения бензоимидазола
KR20060111466A (ko) 2003-09-30 2006-10-27 얀센 파마슈티카 엔.브이. 퀴녹살린 화합물
US7115646B2 (en) 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
US8277831B2 (en) 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
AU2005226729B2 (en) 2004-03-25 2010-01-28 Janssen Pharmaceutica N.V. Imidazole compounds
JPWO2005115993A1 (ja) 2004-05-31 2008-03-27 萬有製薬株式会社 キナゾリン誘導体
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
AU2005278292B2 (en) 2004-08-31 2011-09-08 Msd K.K. Novel substituted imidazole derivatives
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
JP5086809B2 (ja) 2004-12-17 2012-11-28 メルク カナダ インコーポレイテッド ｍＰＧＥＳ−１阻害剤としての２−（フェニルまたはヘテロ環式）−１Ｈ−フェナントロ［９，１０−ｄ］イミダゾール
WO2006102645A1 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
CN101218023B (zh) 2005-07-06 2012-02-08 通用电气健康护理生物科学股份公司 制备分离基质的方法
CA2622372A1 (en) 2005-09-13 2007-03-22 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
JP5301999B2 (ja) 2005-10-31 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｅｔｐ阻害薬
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
WO2007063935A1 (ja) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
CA2643562A1 (en) 2006-02-24 2007-08-30 Anh Chau 2-(phenyl or heterocyclic)-1h-phenanthro[9,10-d]imidazoles
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
DE602007008859D1 (de) 2006-03-31 2010-10-14 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
PL2007752T3 (pl) * 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
EP2010172B1 (en) 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
WO2007120690A2 (en) 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
US20090192158A1 (en) 2006-05-02 2009-07-30 Stacia Kargman Methods for Treating or Preventing Neoplasias
JP2009537460A (ja) 2006-05-18 2009-10-29 メルク フロスト カナダ リミテツド ｍＰＧＥＳ−１阻害剤としてのフェナントレン誘導体
KR20090028819A (ko) 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
US20090181242A1 (en) 2008-01-11 2009-07-16 Enniss James P Exterior window film
MX2010013726A (es) 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina.
MX2010013727A (es) 2008-06-12 2011-01-14 Janssen Pharmaceutica Nv Uso de un antagonista h4 de histamina para el tratamiento de adherencias postoperatorias.
TWI498326B (zh) 2008-06-30 2015-09-01 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
US20100029942A1 (en) 2008-06-30 2010-02-04 Sergio Cesco-Cancian Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US8852569B2 (en) 2008-08-28 2014-10-07 The General Hospital Corporation Prevention and treatment of itch with cysteine protease inhibition
TWI519533B (zh) 2010-11-01 2016-02-01 Ｌｇ生命科學有限公司 １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2465498A1 (en) 2010-11-23 2012-06-20 Faes Farma, S.A. Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
SMT202000084T1 (it) 2013-03-06 2020-03-13 Janssen Pharmaceutica Nv Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina

Also Published As

Publication number Publication date
US8962644B2 (en) 2015-02-24
UY30253A1 (es) 2007-08-31
US9365548B2 (en) 2016-06-14
KR101054325B1 (ko) 2011-08-04
CA2648036A1 (en) 2007-10-18
CY1111169T1 (el) 2015-06-11
CA2648036C (en) 2012-05-22
NI200800260A (es) 2012-01-24
EP2007752A2 (en) 2008-12-31
RS51423B (sr) 2011-02-28
US8343989B2 (en) 2013-01-01
IL244946A0 (en) 2016-05-31
ZA200809328B (en) 2009-12-30
DK2007752T3 (da) 2010-11-15
TW200808737A (en) 2008-02-16
WO2007117399A2 (en) 2007-10-18
CN101460483B (zh) 2013-05-08
US8598189B2 (en) 2013-12-03
BRPI0710083A2 (pt) 2011-08-02
US20150148361A1 (en) 2015-05-28
US20130072510A1 (en) 2013-03-21
DE602007008545D1 (de) 2010-09-30
IL244946A (en) 2017-03-30
ECSP088815A (es) 2008-11-27
SI2007752T1 (sl) 2010-12-31
EP2007752A4 (en) 2009-04-22
EP2007752B1 (en) 2010-08-18
CN101460483A (zh) 2009-06-17
AU2007235576A1 (en) 2007-10-18
CR10413A (es) 2009-02-19
TWI400234B (zh) 2013-07-01
ES2348829T3 (es) 2010-12-15
IL194453A0 (en) 2009-08-03
NZ571691A (en) 2011-07-29
US20140038995A1 (en) 2014-02-06
AU2007235576B2 (en) 2011-11-10
MX2008012655A (es) 2008-12-16
US20070244126A1 (en) 2007-10-18
CO6160328A2 (es) 2010-05-20
PT2007752E (pt) 2010-10-18
PE20080130A1 (es) 2008-02-25
JP5066175B2 (ja) 2012-11-07
UA95949C2 (ru) 2011-09-26
US7507737B2 (en) 2009-03-24
AR059380A1 (es) 2008-04-09
EA016264B1 (ru) 2012-03-30
ATE478067T1 (de) 2010-09-15
US20100256373A1 (en) 2010-10-07
JP2009532366A (ja) 2009-09-10
NO341523B1 (no) 2017-11-27
US20090137608A1 (en) 2009-05-28
KR20080108586A (ko) 2008-12-15
NO20084540L (no) 2008-10-28
ME01143B (me) 2013-03-20
EA200870400A1 (ru) 2009-04-28
WO2007117399A3 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
IL244946A0 (en) Benzoimidazol-2-yl substituted pyrimidine and pyrazine compounds as histamine h4 receptor modulators
IL200335A0 (en) 2-aminopyrimidine modulators of the histamine h4 receptor
ZA200900959B (en) Benzofuro-and benzothienopyrylmidine modulators of the histamine H4 receptor
EP2010172A4 (en) INDOLE AND BENZOIMIDAZOLE AS HISTAMINE H4 RECEPTOR MODULATORS
IL250847A0 (en) 5-substituted quinazolinone derivatives as anticancer agents
ZA200903495B (en) Substituted pyrimidines and their use as JNK Modulators
ZA201100298B (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
ZA200808191B (en) Pyridine and pyrimidine derivatives as MGLUR2 antagonists
IL178597A0 (en) Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
EP2200595A4 (en) THIENO AND FURO PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR
EP2114903A4 (en) BICYCLIC PYRIMIDINONES AND USES THEREOF
IL206413A0 (en) 4-aminopyrimidine derivatives as histamine h4 receptor antagonists
EP2061470A4 (en) HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
ZA200904321B (en) Bicyclic pyrimidinones and uses thereof
HK1138154A (en) 2-aminopyrimidine modulators of the histamine h4 receptor
HK1122035A (zh) 作为组胺h1和h3拮抗剂的2-取代的4-苯基二氮杂萘酮衍生物
HK1144427A (en) Oxypiperidine derivatives as histamine receptor antagonists
HK1126118A (en) Urotensin ii receptor antagonists
HK1131336A (en) Urotensin ii receptor antagonists
HK1130480A (en) Substituted benzamide modulators of the histamine h3 receptor